Dr Reddys Laboratories Ltd (DRREDDY) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 734514, "name": "Dr Reddy's Labs", "stock_name": "Dr Reddy's Labs", "full_name": "Dr Reddys Laboratories Ltd", "name_url": "stocks-analysis/dr-reddy-s-labs", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "1,368.75", "chg": -5.8, "chgp": "-0.42%", "dir": -1, "prev_price": "1,374.55", "mcapval": "114,434.00 Cr", "mcap": "Large Cap", "scripcode": "500124", "symbol": "DRREDDY", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE089A01031", "curr_date": "Jul 06, 03:30 PM", "curr_time": "04:13 AM", "last_traded_at": "Jul 06, 03:30 PM IST", "bse_nse_vol": "8.55 lacs", "exc_status": "Active", "traded_date": "Jul 06, 2026", "traded_date_str": "2026 07 06", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Dr Reddys Laboratories Ltd Valuation Shifts Signal Price Attractiveness Change", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-valuation-shifts-signal-price-attractiveness-change-4089874", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/DrReddysLaborat_valuationdot_4089874.png", "date": "2026-07-06 08:01:05", "description": "Dr Reddys Laboratories Ltd has seen a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting evolving investor sentiment amid a competitive pharmaceutical sector. This article analyses the recent changes in key valuation metrics such as price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical averages and peer benchmarks to assess the stock’s price attractiveness." }, { "title": "Dr Reddys Laboratories Ltd’s Mixed Week: -0.13% Price Change Amid Valuation Shifts and Technical Strength", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltds-mixed-week--013-price-change-amid-valuation-shifts-and-technical-strength-4088904", "imagepath": "", "date": "2026-07-04 16:02:51", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>Jun 29:</strong> New 52-week high at Rs.1,410</p>\n <p><strong>Jun 30:</strong> Valuation shifts to expensive category</p>\n <p><strong>Jul 2:</strong> Modest recovery with 0.52% gain</p>\n <p><strong>Jul 3:</strong> Intraday high surge of 3.21%</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,376.30</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,374.55</div><div class=\"stat-change negative\">-0.13%</div></div>\n ..." }, { "title": "Dr Reddys Laboratories Ltd Rallies 3.21% Surpassing Sector Gains Amid Broad Market Strength", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-intraday-high-with-321-surge-on-3-july-2026-4087853", "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/DrReddysLaborat_priceRelatedfactors_4087853.png", "date": "2026-07-03 13:02:25", "description": "The Sensex advanced 0.69% on 3 Jul 2026, yet Dr Reddys Laboratories Ltd outperformed with a 3.21% gain, marking a notable 1.31 percentage-point lead over its Pharmaceuticals & Biotechnology sector peers. This strong single-session performance stands out as a stock-specific event within a broadly positive market environment." }, { "title": "P/E at 26.67 vs Industry's 35.12: What the Data Shows for Dr Reddys Laboratories Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-shifts-4087154", "imagepath": "", "date": "2026-07-03 09:21:24", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Significance of Nifty 50 Membership</strong></p>\n <p>As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in India’s benchmark equity index, which represents the top 50 companies by free-float market capitalisation on the National Stock Exchange. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). Consequently, the company benefits from sustained liquidity and a steady inflow of institutional capital, factors that often underpin price stability and investor confidence.</p>\n <p>Dr Reddys Laboratories, with a market capitalisation of approximately ₹1,13,332.28 crores, is categorise..." }, { "title": "P/E at 26.6 vs Industry's 35: What the Data Shows for Dr Reddys Laboratories Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4084296", "imagepath": "", "date": "2026-07-02 09:20:59", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Valuation Picture: Discount to Industry P/E</strong></p>\n <p>The current P/E of 26.6 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> represents a discount of approximately 24% relative to the sector average of 34.99. This valuation gap suggests that the market is pricing in either a more conservative growth outlook or perceived risks compared to peers. Given the company’s large-cap status with a market capitalisation of ₹1,11,304.02 crores, such a discount is significant and may reflect sector-specific headwinds or company-specific challenges. The pharmaceutical sector often commands premium valuations due to steady earnings and defensive characteristics, so this divergence merits atte..." }, { "title": "P/E at 27.11 vs Industry's 35.14: What the Data Shows for Dr Reddys Laboratories Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-and-institutional-dynamics-4081121", "imagepath": "", "date": "2026-07-01 09:20:53", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a P/E multiple of 27.11, which is approximately 23% below the Pharmaceuticals & Biotechnology industry average of 35.14. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to peers. Given the sector’s elevated valuations, the stock’s lower P/E could be interpreted as a relative value opportunity or a reflection of company-specific challenges. The market capitalisation stands at a substantial ₹1,13,332.28 crores, confirming its large-cap status within the sector. <a href=\"https://www.marketsmojo..." }, { "title": "Dr Reddys Laboratories Ltd is Rated Hold", "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-hold-4078871", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/DrReddysLaborat_mojoScore_4078871.png", "date": "2026-06-30 10:10:03", "description": "Dr Reddys Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 June 2026, providing investors with an up-to-date view of the company's performance and outlook." }, { "title": "Dr Reddys Laboratories Ltd Valuation Shifts Signal Changing Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-valuation-shifts-signal-changing-market-sentiment-4077709", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/DrReddysLaborat_valuationdot_4077709.png", "date": "2026-06-30 08:01:11", "description": "Dr Reddys Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting evolving investor sentiment amid a competitive pharmaceutical landscape. This article analyses the recent changes in key valuation metrics, compares them with peer averages and historical benchmarks, and assesses the implications for investors." }, { "title": "Broad-Based Technical Strength Lifts Dr Reddys Laboratories Ltd to 52-Week High of Rs 1410", "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-hits-new-52-week-high-at-rs1410-4076608", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/DrReddysLaborat_priceRelatedfactors_4076608.png", "date": "2026-06-29 09:48:38", "description": "With a sustained six-day rally culminating in a fresh 52-week high of Rs 1410 on 29 Jun 2026, Dr Reddys Laboratories Ltd has demonstrated impressive price momentum, outpacing its sector and the broader market despite a flat Sensex opening." } ], "total": 603, "sid": "734514", "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514" }, "announcements": [ { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "01-Jul-2026", "details": "Please find enclosed copy of Newspaper Publication", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "01-Jul-2026", "details": "Please find enclosed copy of Newspaper Publication", "source": "BSE" }, { "caption": "Letter To Shareholders In Relation To Integrated Annual Report Of The Company For FY 2025-26", "datetime": "30-Jun-2026", "details": "Please find enclosed letter to shareholder in relation to Integrated Annual Report of the Company for FY 2025-26", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "", "data": [ { "title": "BOARD MEETING", "txt": "22 Jul 2026" } ] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 26", "dt": "2026-07-10", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24", "dt": "2024-10-28", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06", "dt": "2006-08-28", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

Jun 29: New 52-week high at Rs.1,410

Jun 30: Valuation shifts to expensive category

Jul 2: Modest recovery with 0.52% gain

Jul 3: Intraday high surge of 3.21%

Read full news article

Dr Reddys Laboratories Ltd Rallies 3.21% Surpassing Sector Gains Amid Broad Market Strength

2026-07-03 13:02:25

The Sensex advanced 0.69% on 3 Jul 2026, yet Dr Reddys Laboratories Ltd outperformed with a 3.21% gain, marking a notable 1.31 percentage-point lead over its Pharmaceuticals & Biotechnology sector peers. This strong single-session performance stands out as a stock-specific event within a broadly positive market environment.

Read full news article

P/E at 26.67 vs Industry's 35.12: What the Data Shows for Dr Reddys Laboratories Ltd

2026-07-03 09:21:24

Significance of Nifty 50 Membership

As a constituent of the Nifty 50, Dr Reddys Laboratories Ltd holds a pivotal role in India’s benchmark equity index, which represents the top 50 companies by free-float market capitalisation on the National Stock Exchange. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). Consequently, the company benefits from sustained liquidity and a steady inflow of institutional capital, factors that often underpin price stability and investor confidence.

Dr Reddys Laboratories, with a market capitalisation of approximately ₹1,13,332.28 crores, is categorise...

Read full news article

P/E at 26.6 vs Industry's 35: What the Data Shows for Dr Reddys Laboratories Ltd

2026-07-02 09:20:59

Valuation Picture: Discount to Industry P/E

The current P/E of 26.6 for Dr Reddys Laboratories Ltd represents a discount of approximately 24% relative to the sector average of 34.99. This valuation gap suggests that the market is pricing in either a more conservative growth outlook or perceived risks compared to peers. Given the company’s large-cap status with a market capitalisation of ₹1,11,304.02 crores, such a discount is significant and may reflect sector-specific headwinds or company-specific challenges. The pharmaceutical sector often commands premium valuations due to steady earnings and defensive characteristics, so this divergence merits atte...

Read full news article

P/E at 27.11 vs Industry's 35.14: What the Data Shows for Dr Reddys Laboratories Ltd

2026-07-01 09:20:53

Valuation Picture: Discount Amidst Sector Premiums

Dr Reddys Laboratories Ltd trades at a P/E multiple of 27.11, which is approximately 23% below the Pharmaceuticals & Biotechnology industry average of 35.14. This discount suggests that the market is pricing in either a more conservative growth outlook or risk factors relative to peers. Given the sector’s elevated valuations, the stock’s lower P/E could be interpreted as a relative value opportunity or a reflection of company-specific challenges. The market capitalisation stands at a substantial ₹1,13,332.28 crores, confirming its large-cap status within the sector. Read full news article

Dr Reddys Laboratories Ltd is Rated Hold

2026-06-30 10:10:03

Dr Reddys Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 June 2026, providing investors with an up-to-date view of the company's performance and outlook.

Read full news article

Dr Reddys Laboratories Ltd Valuation Shifts Signal Changing Market Sentiment

2026-06-30 08:01:11

Dr Reddys Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting evolving investor sentiment amid a competitive pharmaceutical landscape. This article analyses the recent changes in key valuation metrics, compares them with peer averages and historical benchmarks, and assesses the implications for investors.

Read full news article

Broad-Based Technical Strength Lifts Dr Reddys Laboratories Ltd to 52-Week High of Rs 1410

2026-06-29 09:48:38

With a sustained six-day rally culminating in a fresh 52-week high of Rs 1410 on 29 Jun 2026, Dr Reddys Laboratories Ltd has demonstrated impressive price momentum, outpacing its sector and the broader market despite a flat Sensex opening.

Read full news article

View All News